Mission-first discipline. Market-rate returns
Healthcare's $4 trillion shift is concentrated in a narrow problem space.
The conditions that consume the majority of U.S. healthcare expenditure — chronic disease, behavioral health, metabolic syndrome, maternal health — are well-documented, structurally underserved, and increasingly addressable by AI-native platforms. Seed stage is where that addressability is built. By the time a health AI company reaches Series A, its clinical assumptions, data architecture, and outcome measurement frameworks are largely set. Investors who enter at seed don't just provide capital — they shape whether a company is built to prove what it claims. That is the window AHV is designed to occupy.
Our Approach
01
We prioritize conditions by morbidity burden and cost concentration before evaluating technology. This filters for companies with clear clinical endpoints, measurable outcome trajectories, and a durable reason to exist beyond a favorable reimbursement environment.
02
Health AI that cannot explain its clinical reasoning, withstand regulatory scrutiny, or document its training data is a liability — not an investment. AHV's diligence includes algorithmic transparency, bias evaluation, FDA and CMS pathway viability, and data governance posture.
03
Every portfolio company is expected to articulate — from day one — how it will measure its impact on patient outcomes, total cost of care, or access to services. This discipline improves the investment, satisfies mission-aligned LP reporting requirements, and positions companies for value-based contracting and payer reimbursement.
Two structural advantages that do not exist together anywhere else at seed stage
Aligned Health Ventures was built with two deliberate structural decisions that distinguish it from every other seed-stage health AI fund. First: AHV has received independent legal confirmation of its eligibility to receive Program Related Investments from private foundations and Mission Related Investments from mission-aligned institutional investors — making foundation capital accessible at seed stage for the first time. Second: BoardKit, a governance product built by AHV and deployed across every portfolio company at investment, creates institutionally auditable board governance from day one — satisfying foundation expenditure responsibility requirements and accelerating portfolio company readiness for Series A, strategic acquirers, and health system commercial partners.
